Low frequency glatiramer acetate therapy
A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.
1. A method of treatment of a human patient suffering from a relapsing form of multiple sclerosis comprising administration to the human patient of three subcutaneous injections of a 40 mg/ml dose of glatiramer acetate per week so as to treat the human patient.
2. The method of claim 1 , wherein the human patient is suffering from relapsing-remitting multiple sclerosis.
3. The method of claim 1 , wherein the human patient has experienced a first clinical episode and has MRI features consistent with multiple sclerosis.
4. The method of claim 2 , wherein the three subcutaneous injections are on three days each week selected from the group consisting of day 1, day 3 and day 5; day 1, day 3 and day 6; day 1, day 4 and day 6; day 2, day 4 and day 6; day 2, day 4 and day 7; 2, day 5 and day 7; and day 3, day 5 and day 7.
5. The method of claim 3 , wherein the three subcutaneous injections are on three days every week selected from the group consisting of day 1, day 3 and day 5; day 1, day 3 and day 6; day 1, day 4 and day 6; day 2, day 4 and day 6; day 2, day 4 and day 7; 2, day 5 and day 7; and day 3, day 5 and day 7.
6. The method of claim 2 , wherein the glatiramer acetate is present in 1 ml of a pharmaceutical composition in a prefilled syringe for self administration by the human patient.
7. The method of claim 3 , wherein the glatiramer acetate is present in 1 ml of a pharmaceutical composition in a prefilled syringe for self administration by the human patient.
8. The method of claim 6 , wherein the pharmaceutical composition further comprises mannitol and has a pH in the range of 5.5 to 7.0.
9. The method of claim 7 , wherein the pharmaceutical composition further comprises mannitol and has a pH in the range of 5.5 to 7.0.
10. A method of treatment of a human patient suffering from a relapsing form of multiple sclerosis comprising subcutaneous injection by the human patient of a 40 mg/ml dose of glatiramer acetate three times per week with at least one day between every subcutaneous injection, wherein the glatiramer acetate is present in 1 ml of a pharmaceutical composition in a prefilled syringe for self injection by the human patient, and wherein the pharmaceutical composition further comprises mannitol and has a pH in the range of 5.5 to 7.0.
11. The method of claim 10 , wherein each subcutaneous injection is on day 1, day 3 and day 5; day 1, day 3 and day 6; day 1, day 4 and day 6; day 2, day 4 and day 6; day 2, day 4 and day 7; 2, day 5 and day 7; or day 3, day 5 and day 7 every week.
12. The method of claim 10 , wherein the human patient is suffering from relapsing-remitting multiple sclerosis.